Refine by
Cancer Monitoring Suppliers & Manufacturers
23 companies found
based inSeoul, SOUTH KOREA
We detect and analyze genomic profile of tumor DNA with a single draw of blood. With this comprehensive profile, we provide personalized and optimized analysis information that can be utilized in therapy selection and monitoring. Ultimately, we ...
based inRedwood City, CALIFORNIA (USA)
Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. We’re developing blood tests for early detection in high-risk populations and ...
based inKillarney, IRELAND
Committed to helping oncology professionals excel in the constantly evolving discipline of oncology and patient ...
ONCOpatient is a digital solution to monitor cancer patients’ health from their homes. This empowers them to manage their condition more effectively with fewer hospital visits and, ultimately, increasing their ...
based inNotting Hill, AUSTRALIA
INOVIQ Ltd (ASX:IIQ) (INOVIQ) is developing and commercialising an innovative portfolio of diagnostic and exosome-based solutions for the earlier detection, diagnosis, prognosis and monitoring of cancer and other diseases to improve patient outcomes ...
INOVIQ’s NETs technology is a sample preparation platform with the potential to revolutionise the performance of liquid biopsy diagnostic assays. The market potential for liquid biopsy applications is estimated at billions of dollars ...
based inAustin, TEXAS (USA)
Asuragen a Bio-Techne brand is a molecular diagnostic product company changing the way patients are treated in genetics and oncology. Asuragen’s diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using ...
based inBethlehem, PENNSYLVANIA (USA)
OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. Together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, OraSure provides its ...
For detection and monitoring of cancers, as well as new biomarker development, a larger volume of urine can be required. Additionally, Colli-Pee® Large Volumes supports multi-omics research. Collector tubes can ...
based inAthens, GREECE
Micrel Medical Devices SA is a medical technology company designing, manufacturing and marketing 'smart' drug delivery systems. We offer a full range of ambulatory volumetric and syringe infusion pumps, administration sets, accessories as well as ...
The Rythmic/ Mini Rythmic Perf+ is an ambulatory pump for infusions with the following delivery modes: Continuous, Volume/Time or Volume/Rate, Auto ramp, Intermittent, 25 Steps. Application areas include as example: Chemotherapy, Antobiotic therapy, ...
based inGuildford, UNITED KINGDOM
Datar Cancer Genetics is a leader in developing blood-based diagnostics that can detect cancer early, offer non-invasive investigations for better treatment options, and track the progression of the disease or its recurrence. We believe that ...
CancertrackTM is a non-invasive blood based investigation that detects cancer derived biomarkers with ultra-high precision, specificity and reliability. CancertrackTM can be used to monitor the disease /recurrence ...
based inVirum, DENMARK
Immudex was created in 2009 when it spun off from the diagnostic company Dako, now Agilent. Since then, Immudex has grown in numbers, employees, patents, product lines, partnerships, and customers served. Research, development, and commercial ...
based inMeyzieu, FRANCE
CTIBiotech uses advanced tissue engineering techniques (3D bioprinting, bioreactors) to develop models and bioassays needed to test the efficiency and effect of ingredients. Our models have varying levels of complexity suited our clients needs in ...
Although much is known about the appearance, growth and spread of cancer in the human body, effective and rapid treatments for many cancer types are yet to be found. Chemo- and radio- therapies have made much progress in the last 20 years, but ...
based inDunedin,, NEW ZEALAND
Pacific Edge is a cancer diagnostics company. We specialise in discovering, building and commercialising innovative cancer diagnostic tests that can contribute to a clinically meaningful difference in the detection and management of cancer. Our ...
Cxbladder is a non-invasive genomic urine test that quickly and accurately detects or rules out bladder cancer. The tests works at a molecular level, measuring five biomarker genes to detect the presence or absence of bladder cancer1, and comes as a ...
based inNew York, NEW YORK (USA)
miR Scientific, LLC is a healthcare company committed to transforming global cancer management by providing early and highly accurate detection, characterization, and monitoring of disease. The Company has developed the miR Disease Management ...
miR Scientific is a precision healthcare company committed to improving public health by transforming cancer management globally. The company’s proprietary miR Disease Management Platform® was developed to revolutionize ...
based inMunich, GERMANY
Therawis Pharma GmbH is a privately held, profitable oncology-specialized company with offices located in Munich, Germany, and was founded in April 2014. We provide european-wide support in medical & clinical trial development for therapeutics and ...
based inSunnyvale, CALIFORNIA (USA)
Olympia Diagnostics is an In Vitro Diagnostics (IVD) company focusing on development and commercialization of the most advanced breakthrough products for cancer diagnosis and prognosis. We developed a proprietary biomarker discovery platform to ...
A diagnostic test kit quantitatively measures the expression levels of a panel of prostate cancer risk-associated biomarkers in patient urine sample or biopsy tissue sample to distinguish high-risk and aggressive prostate cancer needing immediate ...
based inRockville, MARYLAND (USA)
Creatv MicroTech is a privately-held company, founded by Dr. Cha-Mei Tang, which specializes in microfabrication and biodetection. The company’s business is based on cutting-edge research and development - leveraging our expertise in the sciences ...
Personalized Cancer Therapy and Disease Monitoring: “Liquid biopsy” using circulating tumor cells (CTCs) is potentially a minimally invasive alternative to traditional tissue biopsy to determine ...
based inHuntsville, ALABAMA (USA)
SynVivo is a cell-based microfluidic organ-on-chip platform that provides a biologically realistic microenvironment for the real-time study of cellular behavior, drug delivery, and drug discovery. This proprietary technology links the high-tech ...
based inSykesville, MARYLAND (USA)
OTraces, Inc. has built, and extensively filed patents protection on, an early tumor detection and cancer screening software technology. Technology uses well-known math- and physics-based A-I methods including those used in advanced satellite ...
This software is the principal value-add for the company’s instrument systems now being developed for prostate and eventually breast cancer patient monitoring and screening, and access is now being offered to ...
based inAustin, TEXAS (USA)
Natera is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more ...
Signatera is a personalized, tumor-informed assay optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with ...
based inAmsterdam, NETHERLANDS
Self-screen has a long history and track record in translational HPV related science. The company was founded in 2008 to advance the implementation of scientific discoveries in the field of HPV related cancer screening into routine practice. Our ...
based inWest Lafayette, INDIANA (USA)
Tymora Analytical Operations provides diagnostic development and exosome proteomics contract services and products for improved cancer research. Tymora’s primary goal is to enable the shift from tissue to liquid biopsy. Our new technologies allow ...